DelveInsight’s “Sepsis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sepsis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Sepsis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Sepsis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Sepsis: An Overview
Sepsis is a life-threatening organ dysfunction that results from the body’s response to infection. If not recognized early and managed promptly, it can lead to septic shock, multiple organ failure, and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries, where it represents a major cause of maternal and neonatal morbidity and mortality.
According to the World Health Organization (WHO) (2020), “Sepsis is a syndrome of response to infection and is frequently a final common pathway to death from many infectious diseases worldwide.”
Sepsis requires prompt recognition, appropriate antibiotics, careful hemodynamic support, and control of the source of infection. Sepsis can be the clinical manifestation of infections acquired both in the community setting and in health care facilities. Healthcare-associated infections are one of, if not the most frequent, type of adverse event to occur during care delivery and affect hundreds of millions of patients worldwide every year. Since these infections are often resistant to antibiotics, they can rapidly lead to deteriorating clinical conditions. The largest contributors to sepsis cases and sepsis-related mortality across all ages are diarrheal diseases and lower respiratory infections. However, non-communicable diseases are on the rise; one-third of sepsis cases and nearly half of all sepsis-related deaths are due to an underlying injury or chronic disease.
Sepsis Market Key Facts
In 2022, the Sepsis Market Size in the 7MM was approximately USD 2800 Million, which is further expected to increase by 2032.
According to the DelveInsight epidemiology forecast model, in 2022, there were 3,543,000+ cases of sepsis recorded in the 7MM, which is expected to increase by 2032. Of all the 7MM cases, the United States accounted for the maximum share of the Sepsis population with a 55% share in its bucket, making up 1,938,855 cases in 2022.
Assessments as per the DelveInsight epidemiology forecast model, in 2022, there were 1,210,000+ cases of sepsis recorded in EU4 and the UK, which are expected to increase by 2032. Of all the EU countries, Germany accounted for the maximum share of the Sepsis population, with 322,000+ cases in 2022.
Assessments show that in Japan there were 394,000+ incident cases of Sepsis. The epidemiology figures show that Japan’s epidemiology was 11% of the total 7MM patient pool in 2022.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Sepsis pipeline therapies. It also thoroughly assesses the Sepsis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Sepsis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Sepsis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Sepsis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Sepsis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Sepsis Epidemiology, Segmented as –
Sepsis Gender Specific Incident Cases in the 7MM market (2019 to 2032)
Total Sepsis Incident Cases in the 7MM market (2019 to 2032)
Sepsis Severity Specific Incident Cases in the 7MM market (2019 to 2032)
Sepsis Treatable Cases, Sepsis Origin in the 7MM market (2019 to 2032)
Specific Incident Cases in the 7MM market (2019 to 2032)
Sepsis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Sepsis market or expected to be launched during the study period. The analysis covers the Sepsis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Sepsis drugs based on their sale and market share.
The report also covers the Sepsis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Sepsis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Sepsis Market Will Evolve and Grow by 2032 @
Sepsis Therapeutics Analysis
Sepsis is a complex disease, which not only involves a wide array of causative agents but also results in different individual immune responses, causing various single or multiple-organ dysfunction. Treatment for sepsis varies, depending on the site and the cause of the initial infection, the organs affected, and the extent of any damage. Sepsis should be treated as a medical emergency and treated as quickly and efficiently as possible as soon as it has been identified. Sepsis treatment is examined under two categories, with appropriate antimicrobial treatment and all-purpose supporting treatment.
Several major pharma and biotech companies are developing therapies for Sepsis. Currently, SciClone Pharmaceuticals is leading the therapeutics market with its Sepsis drug candidates in the most advanced stage of clinical development.
In June 2023, Basilea Pharmaceuticals announced a study of phase 3 clinical trials for Ceftobiprole medocaril. This research will assess the safety, pharmacokinetics, and effectiveness of ceftobiprole in full-term and pre-term newborns as well as infants up to 3 months old who are affected by late-onset sepsis (LOS). Ceftobiprole, classified as a cephalosporin antibiotic, will be investigated for its potential use in treating LOS in this specific population.
In May 2023, Novartis Pharmaceuticals announced a study of phase 2 clinical trials for TIN816 70 mg lyophilisate powder. The aim of this research is to examine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of TIN816 and assess its safety and tolerability in adult patients admitted to an intensive care unit (ICU) who have been diagnosed with sepsis-related acute kidney injury (SA-AKI).
In June 2020, Ono Pharmaceutical announced that ONO received approval of Onoact (generic name: Landiolol hydrochloride) for Intravenous Infusion 50mg/150mg (“Onoact”), a short-acting selective β1 blocker for the additional indication of tachyarrhythmia (atrial fibrillation, atrial flutter, and sinus tachycardia) associated with sepsis for a partial change in the approved items of the manufacturing and marketing approval in Japan.
Sepsis Companies Actively Working in the Therapeutics Market Include
Some of the key companies in the Sepsis Therapeutics Market include La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
Emerging and Marketed Sepsis Therapies Covered in the Report Include:
Allocetra: Enlivex Therapeutics
BIO-11006: BioMarck Pharmaceuticals
CER-001: ABIONYX Pharma
Esmolol (esmolol hydrochloride): Baxter Healthcare Corporation
Fetroja/Fetcroja (Cefiderocol): Shionogi
M6229: Matisse Pharmaceuticals
Nangibotide (LR12): Inotrem
Onoact Injection (Landiolol hydrochloride): Ono Pharmaceutical
Recombinant human alkaline phosphatase: AM-Pharma
Recombinant human plasma gelsolin: BioAegis Therapeutics
Recomodulin (ART-123): Asahi Kasei Pharma Corp.
STC3141: CGE HealthcareGiapreza: La Jolla Pharmaceuticals
Thymosin alpha 1: SciClone Pharmaceuticals
Vasostrict: Par Pharmaceutical
VBI-S: Vivacelle Bio
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Sepsis Competitive Intelligence Analysis
4. Sepsis Market Overview at a Glance
5. Sepsis Disease Background and Overview
6. Sepsis Patient Journey
7. Sepsis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Sepsis Treatment Algorithm, Current Treatment, and Medical Practices
9. Sepsis Unmet Needs
10. Key Endpoints of Sepsis Treatment
11. Sepsis Marketed Therapies
12. Sepsis Emerging Drugs and Latest Therapeutic Advances
13. Sepsis Seven Major Market Analysis
14. Attribute Analysis
15. Sepsis Market Outlook (In US, EU5, and Japan)
16. Sepsis Companies Active in the Market
17. Sepsis Access and Reimbursement Overview
18. KOL Views on the Sepsis Market
19. Sepsis Market Drivers
20. Sepsis Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Intratumoral Cancer Therapies market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States